Trial Profile

A pivotal phase 3 clinical trial of Metformin delayed release in the patients with Chronic Kidney Disease

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 07 Jun 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Metformin (Primary)
Indications Type 2 diabetes mellitus
Focus Registrational; Therapeutic Use
Acronyms DREAM-CKD
Sponsors Anji Pharma

Most Recent Events

02 Jun 2022 According to a Anji Pharma media release, the company plans to initiate a global Phase 3 trial, DREAM-CKD, to evaluate ANJ900 in T2D patients with advanced CKD (stage 3B and 4) in Q4 2022.
30 Nov 2021 According to an Anji Pharma media release, this study will include 12 countries with topline data expected in 2023.
28 Sep 2021 According to an Anji Pharma media release, the company plans to expand its clinical study of ANJ900 into T2D patients with severe chronic kidney disease in 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com